Long-term administration of the low-dose risperidone in schizotaxia subjects

Hum Psychopharmacol. 2007 Aug;22(6):407-12. doi: 10.1002/hup.863.

Abstract

The term schizotaxia is currently defined as a syndrome of neuropsychological deficits and negative symptoms found in relatives of schizophrenic patients. The aim of this study was to assess the effect of long-term treatment with the low-dose risperidone on cognitive and social functioning in seven schizotaxia patients. There were four males and three females, aged between 17 and 44 years, first-degree (four patients) or second-degree (three patients) relatives of schizophrenic patients. Schizotaxia was recognized in them on account of neuropsychological and social function impairment. They all consented to risperidone administration, 1-2 mg/day. Duration of risperidone treatment has ranged between 3-7 years. In all subjects, the continuous treatment with risperidone brought about a marked improvement in their cognitive, social, and vocational functioning. Neuropsychological testing after 6-24 months showed significant improvement on such tests as Wisconsin Card Sorting Test (WCST), Trail Making Test (TMT), and Stroop Test. Discontinuation of treatment after 3-4 years did not cause deterioration of functioning.

MeSH terms

  • Adolescent
  • Adult
  • Antipsychotic Agents / administration & dosage*
  • Antipsychotic Agents / therapeutic use*
  • Cognition Disorders / drug therapy
  • Drug Administration Schedule
  • Eye Movements / drug effects
  • Female
  • Humans
  • Male
  • Neuropsychological Tests
  • Psychiatric Status Rating Scales
  • Risperidone / administration & dosage*
  • Risperidone / therapeutic use*
  • Schizotypal Personality Disorder / drug therapy*
  • Schizotypal Personality Disorder / physiopathology
  • Schizotypal Personality Disorder / psychology
  • Social Behavior

Substances

  • Antipsychotic Agents
  • Risperidone